KalVista Pharmaceuticals, Inc. Common Stock (KALV) Stock Price

KALVStock

$0.00+53.48%52W

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta0.32

KALV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)78.10%

Price vs S&P 500 (4W)3.02%

VGM Score60.67

Book Value / Share (Quarterly)$0.34

P/TBV (Annual)1.74x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.92

Price vs S&P 500 (YTD)60.80%

Gross Margin (TTM)92.60%

Net Profit Margin (TTM)-91.58%

EPS (TTM)$-1.58

10-Day Avg Trading Volume2.31M

EPS Excl Extra (TTM)$-1.58

Revenue Growth (5Y)31.06%

EPS (Annual)$-2.03

ROI (Annual)-61.30%

Gross Margin (Annual)93.72%

Net Profit Margin (5Y Avg)-402.03%

Cash / Share (Quarterly)$5.56

ROA (Last FY)-32.66%

EBITD / Share (TTM)$-1.56

ROE (5Y Avg)-43.24%

Operating Margin (TTM)-93.90%

Cash Flow / Share (Annual)$-1.64

P/B Ratio84.56x

P/B Ratio (Quarterly)36.20x

Net Income / Employee (Annual)$-398,300

EV / Revenue (TTM)16.37x

Net Interest Coverage (TTM)-43.96x

ROA (TTM)-27.44%

EPS Incl Extra (Annual)$-2.03

Current Ratio (Annual)5.58x

Quick Ratio (Quarterly)4.97x

3-Month Avg Trading Volume2.67M

52-Week Price Return53.48%

Revenue / Employee (TTM)$332,200

Tangible BV / Share (Quarterly)$4.07

P/S Ratio (Annual)29.29x

Asset Turnover (Annual)0.15x

52-Week High$27.00

Operating Margin (5Y Avg)-488.97%

EPS Excl Extra (Annual)$-2.03

CapEx CAGR (5Y)88.34%

Tangible BV CAGR (5Y)42.66%

26-Week Price Return84.17%

Quick Ratio (Annual)5.43x

13-Week Price Return46.42%

Total Debt / Equity (Annual)1.11x

Current Ratio (Quarterly)5.17x

Enterprise Value$1.50B

Revenue / Share Growth (5Y)4.97%

Asset Turnover (TTM)0.30x

Book Value / Share Growth (5Y)-16.43%

Revenue / Employee (Annual)$178,500

Pretax Margin (Annual)-225.27%

Cash / Share (Annual)$5.90

3-Month Return Std Dev90.28%

Net Income / Employee (TTM)$-304,300

ROE (Last FY)-61.30%

Net Interest Coverage (Annual)-1.82x

EPS Basic Excl Extra (Annual)$-2.03

Total Debt / Equity (Quarterly)16.00x

EPS Incl Extra (TTM)$-1.58

ROI (TTM)-76.42%

P/S Ratio (TTM)15.73x

Pretax Margin (5Y Avg)-402.48%

Revenue / Share (Annual)$0.91

Tangible BV / Share (Annual)$4.71

Price vs S&P 500 (52W)35.57%

Year-to-Date Return67.18%

5-Day Price Return0.19%

EPS Normalized (Annual)$-2.03

ROA (5Y Avg)-38.91%

Net Profit Margin (Annual)-223.16%

Month-to-Date Return0.48%

Cash Flow / Share (TTM)$-3.11

EBITD / Share (Annual)$-2.06

Operating Margin (Annual)-228.28%

LT Debt / Equity (Annual)1.11x

ROI (5Y Avg)-43.24%

LT Debt / Equity (Quarterly)15.81x

EPS Basic Excl Extra (TTM)$-1.58

P/TBV (Quarterly)2.01x

P/B Ratio (Annual)7.18x

Pretax Margin (TTM)-94.06%

Book Value / Share (Annual)$1.92

Price vs S&P 500 (13W)39.30%

Beta0.32x

P/FCF (Annual)157.45x

Revenue / Share (TTM)$1.67

ROE (TTM)-237.53%

52-Week Low$10.41

vGradeD

gGradeB

mGradeB

vgmGradeB

KALV Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 14, 2026	-$0.38	-$0.43	-14.29%(-$0.05)
Q4 2025	Mar 25, 2026	-$0.53	$0.94	+278.62%(+$1.47)
Q3 2025	Nov 10, 2025	-$1.04	-$0.92	+11.54%(+$0.12)
Q3 2024	Dec 5, 2024	-$0.91	-$0.91	-0.22%(-$0.00)

KALV Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.92

3.69

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
KALVKalVista Pharmaceuticals, Inc. Common Stock	D	B	B	$0.00
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About KalVista Pharmaceuticals, Inc. Common Stock

KalVista Pharmaceuticals develops oral small-molecule therapies targeting the kallikrein-kinin system for rare genetic and acquired disorders with significant unmet medical needs. The company's commercial product, EKTERLY (sebetralstat), is an FDA-approved plasma kallikrein inhibitor for acute hereditary angioedema (HAE) attacks in patients aged 12 and older. Leveraging its novel oral drug discovery platform, KalVista is positioned to address multiple orphan indications in disease areas with limited treatment options.